ArticleBMC public health2025
An analysis of the burden of respiratory tract cancers in global, China, the United States and India: findings based on the GBD 2021 database.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global burden of respiratory system cancers in 2022 and 2050: incidence and mortality estimates from GLOBOCAN.BMC cancer · 2025Article
- A novel risk score model incorporating six co-stimulatory molecules for accurate prognosis prediction of laryngeal cancer.Translational cancer research · 2025Article
- Global respiratory tumor mortality correlation study with economic level, 2000-2019.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to assess the burden of respiratory tract cancers in China, the United States, India, and worldwide from 1990 to 2021. Also, forecast the evolution of respiratory tract cancers deaths and DALYs burden during 2022 to 2050. STUDY
designAn epidemiological analysis.
methodsBased on the GBD 2021 data, this article analyzed and discussed the trends in burden of respiratory tract cancers in China, the United States, India, and the world from 1990 to 2021. Additionally, the Bayesian Age-Period-Cohort (BAPC) model was used to forecast the evolution of respiratory tract cancers deaths and DALYs burden during 2022 to 2050.
resultsThe ASR-Deaths and ASR-DALYs for laryngeal and TBL cancers decreased globally. The burden of disease for TBL cancer increased in China and India (AAPC: 0.38 and 0.69), especially among Chinese women, while laryngeal cancer declined in India (AAPC: -0.69). In contrast, the burden of disease for both cancers declined substantially in the United States (-1.82 AAPC for laryngeal cancer and - 1.74 AAPC for TBL). A notable gender disparity existed in the burden of respiratory tumors, with males experienced a higher disease burden compared to females. In terms of age, the peak incidence of respiratory tract cancers predominantly occurred among individuals aged 65-74, indicating a clear tendency towards a higher prevalence among this age group. Population growth and ageing were primary factors influencing the mortality burden of larynx cancer, whereas epidemiological shifts in TBL cancer markedly impacted DALYs. The forecasted results for ASR-Deaths and ASR-DALYs worldwide from 2022 to 2050 indicated a decline in the burden of both larynx and TBL cancers. However, the deaths and DALYs of TBL cancer in China will show an upward trend, especially for females.
conclusionsThe disease burden of respiratory tract cancers is a global health issue that needs attention, and situations vary from country to country, requiring personalized measures. Global strategies must address aging populations and socioeconomic disparities to reduce inequities in high-burden regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.